NASDAQ:AMED - Amedisys Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$127.12 +0.23 (+0.18 %)
(As of 01/20/2019 10:29 AM ET)
Previous Close$127.12
Today's Range$124.67 - $128.3407
52-Week Range$49.98 - $140.91
Volume302,270 shs
Average Volume320,533 shs
Market Capitalization$4.05 billion
P/E Ratio38.52
Dividend YieldN/A
Beta1.43
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.53 billion
Cash Flow$2.7635 per share
Book Value$15.22 per share

Profitability

Net Income$30.30 million

Miscellaneous

Employees17,900
Market Cap$4.05 billion
OptionableOptionable

Amedisys (NASDAQ:AMED) Frequently Asked Questions

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) announced its quarterly earnings data on Monday, October, 29th. The health services provider reported $0.95 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.77 by $0.18. The health services provider had revenue of $417.34 million for the quarter, compared to the consensus estimate of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The company's revenue was up 11.7% on a year-over-year basis. During the same period last year, the firm earned $0.56 EPS. View Amedisys' Earnings History.

When is Amedisys' next earnings date?

Amedisys is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Amedisys.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY18 earnings guidance on Monday, October, 29th. The company provided earnings per share (EPS) guidance of $3.54-3.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.40. The company issued revenue guidance of $1.65-1.67 billion, compared to the consensus revenue estimate of $1.65 billion.Amedisys also updated its FY 2018 guidance to $3.54-3.60 EPS.

What price target have analysts set for AMED?

13 brokerages have issued 1-year price objectives for Amedisys' stock. Their predictions range from $63.00 to $139.00. On average, they anticipate Amedisys' stock price to reach $110.9231 in the next twelve months. This suggests that the stock has a possible downside of 12.7%. View Analyst Price Targets for Amedisys.

What is the consensus analysts' recommendation for Amedisys?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amedisys.

Has Amedisys been receiving favorable news coverage?

News coverage about AMED stock has trended extremely positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a coverage optimism score of 4.1 on InfoTrie's scale. They also gave media headlines about the health services provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.

Who are some of Amedisys' key competitors?

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:
  • Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
  • Mr. Michael P. North, Chief Information Officer (Age 54)
  • Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Boston Advisors LLC (0.14%), Navellier & Associates Inc (0.06%), Nisa Investment Advisors LLC (0.05%), Bowling Portfolio Management LLC (0.04%), Louisiana State Employees Retirement System (0.03%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Lawrence R Pernosky, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and Louisiana State Employees Retirement System. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Michael Paul North and Scott G Ginn. View Insider Buying and Selling for Amedisys.

Which major investors are buying Amedisys stock?

AMED stock was acquired by a variety of institutional investors in the last quarter, including Navellier & Associates Inc, Boston Advisors LLC, Bowling Portfolio Management LLC, Meeder Asset Management Inc., State of Alaska Department of Revenue and First Hawaiian Bank. View Insider Buying and Selling for Amedisys.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $127.12.

How big of a company is Amedisys?

Amedisys has a market capitalization of $4.05 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys employs 17,900 workers across the globe.

What is Amedisys' official website?

The official website for Amedisys is http://www.amedisys.com.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]


MarketBeat Community Rating for Amedisys (NASDAQ AMED)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  442 (Vote Underperform)
Total Votes:  720
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel